VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Zandberg on the Role of Immunotherapy in Head and Neck Cancer

Dan Zandberg, MD
Published: Tuesday, Oct 17, 2017



Dan Zandberg, MD, assistant professor of medicine, University of Maryland School of Medicine, discusses the role of immunotherapy in head and neck cancer.

With immunotherapy, these single agents are being combined with targeted agents and with other immunotherapy agents, including durvalumab (Imfinzi), in an effort to enhance the amount of patients who benefit from immunotherapy, says Zandberg.

At the 2017 ASCO Annual Meeting, there were combinations with IDO inhibitors that showed promising results, explains Zandberg. The combination of anti


Dan Zandberg, MD, assistant professor of medicine, University of Maryland School of Medicine, discusses the role of immunotherapy in head and neck cancer.

With immunotherapy, these single agents are being combined with targeted agents and with other immunotherapy agents, including durvalumab (Imfinzi), in an effort to enhance the amount of patients who benefit from immunotherapy, says Zandberg.

At the 2017 ASCO Annual Meeting, there were combinations with IDO inhibitors that showed promising results, explains Zandberg. The combination of anti

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x